Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Publikováno v:
European Journal of Clinical Pharmacology
European Journal of Clinical Pharmacology, Springer Verlag, 2009, 66 (2), pp.165-170. ⟨10.1007/s00228-009-0741-5⟩
European Journal of Clinical Pharmacology, Springer Verlag, 2009, 66 (2), pp.165-170. ⟨10.1007/s00228-009-0741-5⟩
Purpose In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam (OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently unknown whether the glucuronidation of OHM to 1-OH-midazolam glucuronide (OHMG
Autor:
Sun Ah Yang-Reid, Georgialina Rodriguez, Derrick M. Oaxaca, Jeremy A. Ross, Robert A. Kirken, Joan G. Staniswalis
Publikováno v:
Tumour Biology
Tyrosine kinase inhibitors (TKIs) have dramatically improved the life expectancy of patients suffering from chronic myeloid leukemia (CML); however, patients will eventually develop resistance to TKI therapy or adverse side effects due to secondary o
Autor:
Shinichi Kinami, Katsunobu Oyama, Yuki Takai, Takashi Fujimura, Shigekazu Ohyama, Tetsuo Ohta, Naotaka Kadoya, Masahide Kaji, Hideaki Nezuka, Kunihiro Tsuji, Toshiya Takeda, Sachio Fushida, Tomoya Tsukada, Yuji Tsukioka, Kazuhisa Yabushita, Jun Kinoshita
Publikováno v:
International Journal of Clinical Oncology
Purpose The purpose of our study was to evaluate the efficacy of a new combination antiemetic therapy consisting of palonosetron, aprepitant, and dexamethasone in gastric cancer patients undergoing chemotherapy with S-1 plus cisplatin. Methods This p
Autor:
Per-Henrik Edqvist, Gunilla Enblad, Anca Dragomir, Marjut Niinivirta, Fredrik Pontén, Gustav J. Ullenhag
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Tyrosine kinase inhibitors like sunitinib and sorafenib are commonly used to treat metastatic renal cell cancer patients. Cubilin is a membrane protein expressed in the proximal renal tubule. Cubilin and megalin function together as endocytic
Autor:
Tomasz Powrózek, Iwona Homa, Radosław Mlak, Monika Prendecka, Piotr Kozioł, Teresa Małecka-Massalska, Paweł Krawczyk, Marzanna Ciesielka, Janusz Milanowski
Publikováno v:
Clinical & Translational Oncology
Purpose Chemotherapy with platinum compounds and gemcitabine is frequently used in first-line treatment of advanced non-small cell lung cancer (NSCLC) patients in which tyrosine kinase inhibitors (EGFR or ALK) cannot be administered. Unfortunately, l
Publikováno v:
Journal of Biomedical Science
The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first-line treatments for advanced EGFR mutation-positive non-small ce
Publikováno v:
Journal of Medical Case Reports
Background Hepatic pregnancy is a rare form of abdominal pregnancy, often documented only as case reports. Case presentation We report here the case of a 24-year-old African woman, gravida 4 para 3, presenting with right upper quadrant pains and metr
Publikováno v:
BMC Medicine
In recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies has dramatically improved the clinical outcomes for patients with advanced melanoma. These antagonist monoclonal antibodies are capab
Autor:
Nan Li, Elizabeth Mazzio, Leeshawn Thomas, Equar Taka, David Bauer, Karam F.A. Soliman, Patricia Mendonca, Mohammed Darb, Henry N. Williams
Publikováno v:
BMC Complementary and Alternative Medicine
Background Acute systemic inflammatory response syndrome arising from infection can lead to multiple organ failure and death, with greater susceptibility occurring in immunocompromised individuals. Moreover, sub-acute chronic inflammation is a contri
Autor:
Nuno Almeida, Adriano Casela, José Eduardo Pina Cabral, Maria Manuel Donato, Luís Tomé, Carlos Gregório, Diogo Branquinho
Publikováno v:
BMC Gastroenterology
Background Helicobacter pylori eradication rates in Portugal are declining, due to increased resistance of this bacterium to antimicrobial agents, especially Clarithromycin. Quadruple Levofloxacin-containing regimens could be an option for first-line